Jobs / United States / Glaxosmithkline LLC
Principal Scientist, Predictive Sciences
Glaxosmithkline LLC · 🇺🇸 2 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Glaxosmithkline LLC paid sponsored hires in similar roles8 certified filings for “Principal Scientist” (Medical Scientists, Except Epidemiologists) in PA: $98k–$110k, median $98k. Most were filed at wage level I (63%) — 1 lottery entry, ≈15% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Glaxosmithkline LLC
The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Glaxosmithkline LLC →
About the role
We are building the next generation of biologics CMC with a rapid, efficient, and predict-first mindset. As a Principal Scientist in the Predictive Sciences group within our new CMC Digital and Knowledge Management department, you will sit at the intersection of late-phase CMC process development and design of cutting-edge digital tools, predictive solutions, and artificial intelligence that accelerate how we bring medicines from bench to patient. Biologics CMC is undergoing a fundamental shift, moving away from empirical and experiment-heavy development towards a predict-first, digitally augmented, and model-informed development. You will help define what that shift looks like, building tools and ways of working that will have an impact on the entirety of portfolio and shape how we develop medicines. You will be an AI-native builder who takes mechanistic, hybrid and data-driven models from prototype to production. This role will deploy models through machine learning workflows and agentic AI systems that actively drive development decisions across upstream and downstream unit operations for biologics process development across our fed-batch, intensified fed-batch and continuous perfusion platforms. Strong modelling expertise is required and expected; equal weight is placed on the ability to ship those models into a form scientists can run independently, through deployment, product build and model lifecycle management. This role will also impact tech transfer, scale-up and commercialization of processes, and requires a proven ability to drive digital transformation principles across the business, with the agility to lead change. This role sits within Predictive Sciences, in the CMC Digital & Knowledge Management department, reporting to the Team Lead for LM Drug Substance Development modelling. You will work in close partnership with process development, analytical development, and manufacturing science teams, and collaborate with the broader GSK digital science and data communities to share platforms, capabilities, and best practices. As a Principal Scientist you are an individual contributor with high scientific autonomy. You are expected to influence the direction of digital CMC through the quality of your technical contributions and the trust you build with scientific partners. This role will provide you the opportunity to lead key activities to progress your career, these responsibilities include some of the following: Modeling & Simulation • Build and deploy advanced process models: mechanistic, hybrid, and data-driven across upstream cell culture, chromatography, filtration, and formulation, including digital twins and PAT chemometric models for current and evolving continuous perfusion and capture platforms. Leverage engineering, biological, chemical, or materials science knowledge to postulate mechanisms for bioprocess behavior and develop or modify existing mathematical models to describe those mechanisms • Drive model-informed process development and characterization as an embedded matrix team member, using MBDoE and model-based risk assessments to define critical process parameters, design space, in-silico experimentation, reduce wet-lab cycle, accelerate process understanding, platform fit, and model-based monitoring and process control strategies. • Translate science into software by converting mathematical models into working computational tools via platforms (gPROMS, SIMCA, JMP) or custom code (Python, MATLAB), and ensure models are validated to meet GSK internal compliance and regulatory requirements. • Champion adoption of digitally redesigned CMC workflows across the Drug Development and Supply organization , supporting the CMC portfolio through GSK enterprise-wide digital trans